HYBRITECH TANDEM-R OSTASE RADIOIMMUNOASSAY CLEARED FOR POSTMENOPAUSAL OSTEOPOROSIS MANAGEMENT INDICATION; EIA VERSION UNDER DEVELOPMENT
This article was originally published in The Gray Sheet
Executive Summary
Hybritech is promoting its Tandem-R Ostase radioimmunoassay for use in the management of postmenopausal osteoporosis following FDA clearance of the new indication via 510(k) in August. The company began promoting the product for the expanded indication at the Sept. 7-11 American Society of Bone and Mineral Research meeting in Seattle.